NASDAQ:OTLK - Outlook Therapeutics Stock Price, Forecast & News

Outlook Therapeutics trades on the NASDAQ under the ticker symbol "OTLK."

Outlook Therapeutics's stock reverse split before market open on Monday, March 18th 2019. The 1-8 reverse split was announced on Friday, March 15th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 15th 2019. An investor that had 100 shares of Outlook Therapeutics stock prior to the reverse split would have 13 shares after the split.

Outlook Therapeutics, Inc. (NASDAQ:OTLK) issued its quarterly earnings results on Thursday, December, 19th. The company reported ($0.12) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.31) by $0.19. The firm earned $5.85 million during the quarter, compared to the consensus estimate of $0.63 million. View Outlook Therapeutics' Earnings History.

Outlook Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Outlook Therapeutics.

5 equities research analysts have issued twelve-month price objectives for Outlook Therapeutics' shares. Their forecasts range from $4.00 to $12.00. On average, they expect Outlook Therapeutics' stock price to reach $9.00 in the next year. This suggests a possible upside of 765.4% from the stock's current price. View Analyst Price Targets for Outlook Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Outlook Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Outlook Therapeutics.

News articles about OTLK stock have been trending positive this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Outlook Therapeutics earned a daily sentiment score of 3.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Outlook Therapeutics.

Outlook Therapeutics saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 2,000,000 shares, an increase of 13.6% from the December 15th total of 1,760,000 shares. Based on an average trading volume of 861,100 shares, the short-interest ratio is presently 2.3 days. Approximately 14.2% of the shares of the company are sold short. View Outlook Therapeutics' Current Options Chain.

Some companies that are related to Outlook Therapeutics include Acorda Therapeutics (ACOR), Brainstorm Cell Therapeutics (BCLI), Champions Oncology (CSBR), Surface Oncology (SURF), Polarityte (PTE), Microbot Medical (MBOT), Genocea Biosciences (GNCA), BIONDVAX PHARMA/S (BVXV), Pharmacyte Biotech (PMCB), Allena Pharmaceuticals (ALNA), Pluristem Therapeutics (PSTI), INmune Bio (INMB), Idera Pharmaceuticals (IDRA), Organovo (ONVO) and Curis (CRIS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Outlook Therapeutics investors own include AzurRx BioPharma (AZRX), Onconova Therapeutics (ONTX), Biocept (BIOC), Sierra Oncology (SRRA), Big 5 Sporting Goods (BGFV), Lockheed Martin (LMT), FuelCell Energy (FCEL), Strongbridge Biopharma (SBBP), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

Shares of OTLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OTLK stock can currently be purchased for approximately $1.04.

Outlook Therapeutics has a market capitalization of $29.36 million and generates $8.15 million in revenue each year. The company earns $-34,520,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis. Outlook Therapeutics employs 56 workers across the globe.View Additional Information About Outlook Therapeutics.

The official website for Outlook Therapeutics is http://www.outlooktherapeutics.com/.

Outlook Therapeutics' mailing address is 7 CLARKE DRIVE, CRANBURY NJ, 08512. The company can be reached via phone at 609-619-3990 or via email at [email protected]